What does a Wegovy 1 month supply actually include?

What does the pen contain, and how does one month of doses work?

Wegovy arrives as a pre-filled, single-use injection pen made by Novo Nordisk. One pen delivers four doses (one per week) so a monthly supply is simply one pen at whatever strength your prescriber has approved. The pen is designed to be injected subcutaneously, typically into the abdomen, thigh or upper arm, with the site rotated each week.

The strength printed on the pen matters enormously. Early in treatment that pen will be 0.25mg; after roughly four weeks, if your prescriber agrees you have tolerated it well, the next month steps to 0.5mg, then 1.0mg, then 1.7mg, and eventually the 2.4mg maintenance dose. In April 2026 the MHRA also approved a dedicated single-dose 7.2mg pen as a new maximum for eligible adults, with its own titration path. The full Wegovy treatment overview covers what these steps look like across the whole programme.

Storage is refrigerated at 2–8°C, keep it in the fridge until you are ready to use it. The pen must never be frozen. Exact guidance on the room-temperature window once removed from the fridge is in your Patient Information Leaflet; follow that, not informal estimates. One practical note: the pen fits neatly in the fridge door and travels well in a cool bag for short trips.

A question our prescribers hear most weeks is whether patients should be taking the 0.25mg pen more than once a week to speed things up. The schedule is one injection per week, and the timing between doses is fixed for a reason, stacking doses increases the risk of side effects without adding benefit.

What changes are realistic after one month on Wegovy?

The first month is largely about tolerability, not transformation. The 0.25mg starting dose is below the level that produces meaningful appetite suppression for most people; its job is to condition your digestive system so that subsequent doses are better tolerated. Many people notice mild nausea, some change in appetite, and occasionally looser stools or indigestion, the most common effects reported in clinical trials were gastrointestinal, typically mild to moderate and settling within the first couple of weeks at each new dose.

The detailed picture of what happens in month one includes realistic timelines and what counts as a normal adjustment versus a reason to contact your prescriber. The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks; the average weight reduction of around 15% built up progressively over that period, with meaningful results becoming more visible at the higher maintenance doses. One month at 0.25mg is the foundation, not the result.

If you are transferring from another provider at a higher dose, that is a different clinical picture, your prescriber will need evidence of your current treatment before approving a supply at a dose above the starter. That protects you as much as it protects the integrity of the prescription process.

Is a month's supply of Wegovy reliably available in the UK right now?

This is where things get practical and honest. Wegovy has faced genuine availability pressures in the UK since demand accelerated following its licensing. The situation shifts from month to month and varies by dose, lower doses have generally been easier to source than the maintenance strengths. Before committing to a treatment plan, it is worth reading the current Wegovy supply situation in the UK, which tracks what is known from Novo Nordisk and pharmacy-level stock information.

A GPhC-registered pharmacy can only dispense what it can legally source through the licensed UK supply chain. Buying from unverified sellers (particularly those advertising on social media or offering Wegovy without a clinical assessment) carries real risks: the MHRA has seized fake weight-loss pens that contained insulin rather than semaglutide, causing serious harm. You can verify any online pharmacy on the GPhC register in under a minute.

If your dose is temporarily unavailable, that is a clinical conversation, not a DIY decision. Skipping weeks, splitting doses or substituting a different medicine without prescriber input are all routes to losing the progress you have made or encountering avoidable side effects. The supply issues page covers what to do while waiting. For a broader sense of UK-wide availability patterns, the Wegovy supply in the UK overview is also worth reading.

What does a month's private supply cost, and what should that price include?

Private Wegovy pricing has shifted significantly since Eli Lilly's list-price increase for Mounjaro in late 2025 changed the market benchmark. Wegovy's private cost varies by dose and provider; as a general guide, reported market prices since mid-2025 have ranged from roughly £149 to £375 per monthly pen. The full cost breakdown for Wegovy sets out what these figures mean in practice.

What a price should include matters as much as the number itself. A legitimate private prescription for a POM covers a clinical consultation, the prescription itself, the dispensed medicine, and (at a well-run pharmacy) next-working-day delivery and ongoing prescriber access. If a price quote omits any of those elements, or if the total looks far below the market range, treat that as a flag rather than a bargain. At nume, one transparent price covers the consultation, prescription, medicine, free next-working-day DPD delivery in plain packaging, and 7-day aftercare. For a prescription medicine, the cheapest listing answers the wrong question. See the three-month supply page if you want to understand how longer supply periods work in practice.

If you are ready to find out whether Wegovy is clinically suitable for you, the right starting point is a free consultation reviewed the same day by a GPhC-registered prescriber. Start your free consultation and get a clinical answer, not a sales pitch.